Triple-negative breast cancer: an update on neoadjuvant clinical trials.

Abstract

Triple-negative breast cancer (TNBC) is an aggressive malignancy with a poor prognosis despite the high rates of response to chemotherapy. This scenario highlights the need to develop novel therapies and/or treatment strategies to reduce the mortality associated with TNBC. The neoadjuvant setting provides a model for rapid assessment of treatment efficacy with smaller patient accruals and over shorter periods of time compared to the traditional adjuvant setting. In addition, a clear surrogate endpoint of improved survival, known as pathologic complete response, already exists in this setting. Here, we review current data from completed and ongoing neoadjuvant clinical trials for TNBC.

• Authors: Keith D Amos, Barbara Adamo, Carey K Anders
• Journal: International journal of breast cancer (Int J Breast Cancer) Vol. 2012 Pg. 385978 ( 2012) ISSN: 2090-3189 [Electronic] Egypt
• PMID: 22461984 (Publication Type: Journal Article)